108 related articles for article (PubMed ID: 15034845)
1. Apparent failure of moxifloxacin to prevent ciprofloxacin- and levofloxacin-susceptible Pseudomonas aeruginosa bacteremia in neutropenic patients undergoing peripheral blood stem cell transplantation.
Prabhu RM; Elliott MA; Patel R
Clin Infect Dis; 2004 Apr; 38(7):1043-5. PubMed ID: 15034845
[No Abstract] [Full Text] [Related]
2. Microbiological rationale for the utilisation of prulifloxacin, a new fluoroquinolone, in the eradication of serious infections caused by Pseudomonas aeruginosa.
Roveta S; Schito AM; Marchese A; Schito GC
Int J Antimicrob Agents; 2005 Nov; 26(5):366-72. PubMed ID: 16216467
[TBL] [Abstract][Full Text] [Related]
3. Moxifloxacin prophylaxis in neutropenic patients.
von Baum H; Sigge A; Bommer M; Kern WV; Marre R; Döhner H; Kern P; Reuter S
J Antimicrob Chemother; 2006 Oct; 58(4):891-4. PubMed ID: 16880172
[TBL] [Abstract][Full Text] [Related]
4. An in vitro investigation of levofloxacin and ciprofloxacin against clinical isolates of Pseudomonas aeruginosa.
Segatore B; Perilli M; Larosa M; Setacci D; Celenza G; Amicosante G
Int J Antimicrob Agents; 2007 Oct; 30(4):374-6. PubMed ID: 17659863
[No Abstract] [Full Text] [Related]
5. Levofloxacin-imipenem combination prevents the emergence of resistance among clinical isolates of Pseudomonas aeruginosa.
Lister PD; Wolter DJ
Clin Infect Dis; 2005 Feb; 40 Suppl 2():S105-14. PubMed ID: 15712098
[TBL] [Abstract][Full Text] [Related]
6. In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point.
Alkorta M; Giménez MJ; Vicente D; Aguilar L; Pérez-Trallero E
Int J Antimicrob Agents; 2005 Feb; 25(2):163-7. PubMed ID: 15664487
[TBL] [Abstract][Full Text] [Related]
7. Comparison of antibiotic effect and corneal epithelial toxicity of levofloxacin and moxifloxacin in vitro.
Kim SY; Lim JA; Choi JS; Choi EC; Joo CK
Cornea; 2007 Jul; 26(6):720-5. PubMed ID: 17592324
[TBL] [Abstract][Full Text] [Related]
8. Bacteremia due to viridans group Streptococci with diminished susceptibility to Levofloxacin among neutropenic patients receiving levofloxacin prophylaxis.
Razonable RR; Litzow MR; Khaliq Y; Piper KE; Rouse MS; Patel R
Clin Infect Dis; 2002 Jun; 34(11):1469-74. PubMed ID: 12015693
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of meropenem in combination with ciprofloxacin against clinical isolates of Pseudomonas aeruginosa.
Solak S; Willke A; Ergönül O; Tekeli E
Int J Antimicrob Agents; 2005 Feb; 25(2):181-2. PubMed ID: 15664492
[No Abstract] [Full Text] [Related]
10. Levofloxacin, a broad spectrum anti-infective: from Streptococcus pneumoniae to Pseudomonas aeruginosa.
Schito AM; Schito GC
J Chemother; 2004 Apr; 16 Suppl 2():3-7. PubMed ID: 15255554
[No Abstract] [Full Text] [Related]
11. Morphological changes in Pseudomonas aeruginosa secondary to ciprofloxacin.
Suvarna SK; al-Wali WI; Locke TJ
Histopathology; 1997 Nov; 31(5):482-3. PubMed ID: 9416493
[No Abstract] [Full Text] [Related]
12. Moxifloxacin versus standard therapy in patients with pneumonia hospitalized after failure of preclinical anti-infective treatment.
Wenisch C; Krause R; Széll M; Laferl H
Infection; 2006 Aug; 34(4):190-5. PubMed ID: 16896576
[TBL] [Abstract][Full Text] [Related]
13. In vivo oral efficacy of levofloxacin for treatment of systemic Pseudomonas aeruginosa infections in a murine model of septicemia.
Yagel SK; Barrett JF; Amaratunga DJ; Frosco MB
Antimicrob Agents Chemother; 1996 Dec; 40(12):2894-7. PubMed ID: 9124863
[TBL] [Abstract][Full Text] [Related]
14. Simulated comparison of the pharmacodynamics of ciprofloxacin and levofloxacin against Pseudomonas aeruginosa using pharmacokinetic data from healthy volunteers and 2002 minimum inhibitory concentration data.
Burgess DS; Hall RG
Clin Ther; 2007 Jul; 29(7):1421-7. PubMed ID: 17825693
[TBL] [Abstract][Full Text] [Related]
15. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
Schein J; Janagap-Benson C; Grant R; Sikirica V; Doshi D; Olson W
Curr Med Res Opin; 2008 Mar; 24(3):895-906. PubMed ID: 18419876
[TBL] [Abstract][Full Text] [Related]
16. Comparing the protective effects of ciprofloxacin, moxifloxacin and levofloxacin in mice with lipopolysaccharide-induced acute lung injuries.
Huang HC; Shieh CC; Yu WL; Cheng KC; Chen CC; Chang ST; Chuang YC
Respirology; 2008 Jan; 13(1):47-52. PubMed ID: 18197910
[TBL] [Abstract][Full Text] [Related]
17. Selection of cross-resistance following exposure of Pseudomonas aeruginosa clinical isolates to ciprofloxacin or cefepime.
Alyaseen SA; Piper KE; Rouse MS; Steckelberg JM; Patel R
Antimicrob Agents Chemother; 2005 Jun; 49(6):2543-5. PubMed ID: 15917569
[TBL] [Abstract][Full Text] [Related]
18. Moxifloxacin versus levofloxacin against acute exacerbations of chronic bronchitis: the Latin American Cohort.
Urueta-Robledo J; Ariza H; Jardim JR; Caballero A; García-Calderón A; Amábile-Cuevas CF; Hernández-Oliva G; Vivar-Orozco R;
Respir Med; 2006 Sep; 100(9):1504-11. PubMed ID: 16504492
[TBL] [Abstract][Full Text] [Related]
19. Is levofloxacin as active as ciprofloxacin against Pseudomonas aeruginosa?
Bonfiglio G
Chemotherapy; 2001; 47(4):239-42. PubMed ID: 11399859
[TBL] [Abstract][Full Text] [Related]
20. Emergence of ciprofloxacin-resistant pseudomonas in chronic suppurative otitis media.
Jang CH; Park SY
Clin Otolaryngol Allied Sci; 2004 Aug; 29(4):321-3. PubMed ID: 15270816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
